Stimulation of endothelial cells resulted in release of arachidonic acid from phospholipids. The magnitude of this response decreased as the cells became confluent and the change coincided with a decrease in the percentage of cells in growth phases (G2 + M); this was not a consequence of time in culture or a factor in the growth medium. Preconfluent cells released 30% of arachidonic acid; confluent cells released only 6%. The decreasing release of arachidonic acid was demonstrated using metabolic labeling, mass measurements of arachidonic acid, and measurement of PGI2. The decrease was not due to a changing pool of arachidonic acid, and mass measurements showed no depletion of arachidonic acid. Release from each phospholipid and from each phospholipid class decreased with confluence. Conversion of confluent cells to the proliferative phenotype by mechanical wounding of the monolayer caused increased release of arachidonic acid. Potential mechanisms for these changes were investigated using assays of phospholipase activity. Phospholipase A2 activity changed in concert with the alteration in release, a consequence of changes in phosphorylation of the enzyme. The increased release of arachidonic acid from preconfluent, actively dividing cells may have important physiologic implications and may help elucidate mechanisms regulating release of arachidonic acid. (J. Clin.
Introduction
Oxidative metabolites of arachidonic acid (eicosanoids) are a diverse group of bioactive lipids which are produced in response to appropriate stimulation by a variety of cells, including endothelial cells (1) (2) (3) (4) . The synthesis and secretion of PGI2 and other arachidonic acid metabolites by endothelial cells are thought to modulate vascular tone and the interaction with blood cells (5) (6) (7) . Thus, the regulation of arachidonic acid metabolism in endothelial cells has an important role in vascular physiology. In addition to these actions, recent work suggests that arachidonic acid metabolites, or more precisely metabolites of the cyclooxygenase pathway, play a role in proliferation and neo-plasia. This includes studies implicating eicosanoids in the regulation of growth in other cells (8, 9) and tissues, including colonic polyps and cancer of the colon (10, 11) . One group has found evidence that arachidonic acid metabolites are synergistic with certain growth factors in mediating endothelial cell mitogenesis (12) . In addition, studies from several laboratories have shown recently that cytokines cause expression of novel eicosanoid pathway enzymes, including a second, inducible, prostaglandin H2 synthetase found in several cell types, including endothelial cells (13) . Many phenotypic changes occur in cultured endothelial cells as they progress from an actively dividing, preconfluent cell to a contact-inhibited monolayer. Several studies have shown that the ability of endothelial cells to produce PGI2 changes as the cells are maintained in culture, particularly with multiple passes (1, (14) (15) (16) . Thus, there is evidence that arachidonic acid metabolism is in some way related to the growth state of endothelial cells in culture. Taken together, these data suggest that an arachidonic acid metabolite may regulate proliferation or play a role in unregulated proliferation.
Endothelial cells are a good model system for study of these issues because they can be cultured in highly purified populations, and arachidonic acid metabolism is under the control of well-characterized intracellular signals induced by a variety of agonists. The spectrum of eicosanoids produced varies among endothelial cell types, but, in macrovascular endothelial cells, the predominant product is PGI2. Synthesis of eicosanoids begins with the release of arachidonic acid from phospholipid stores (17, 18) . This release does not occur constitutively but requires stimulation of the cells with specific agonists (1, 19, 20) . Arachidonic acid is stored as an esterified fatty acid in phospholipids, usually at the sn-2 position (21) . Release of arachidonic acid upon stimulation is believed to occur by the action of phospholipase(s), usually by a phospholipase A2 (PLA2)1 that releases arachidonic acid directly, or in concert with a transacylase (22, 23) . Alternatively, release can result from a phospholipase C that hydrolyzes the phospholipid to diacylglycerol, followed by diglyceride and monoglyceride lipases that release arachidonic acid. There is evidence for each of these pathways in several cell types (7, 24, 25) , and the relative contribution of each to total arachidonic acid release is not known. Similarly, the mechanisms that govern the activation of the phospholipase(s) are not completely understood. It is clear that a rise in intracellular calcium concentrations is necessary for release of arachidonic acid (7, 26) and that entry of extracellular calcium is necessary for a full response in most cell types (26) . There is evidence in endothelial cells that phospholipases C and D are activated concurrently with a rise in cellular calcium and PGI2 production (7, (27) (28) (29) , but the contribution of these phospholipase activities to total arachidonic acid release is not known. Several groups have purified a cytoplasmic PLA2 that is selective for arachidonic acid at the sn-2 position (30) (31) (32) (33) (34) (35) . Moreover, this enzyme translocates to cell membranes and is activated in response to calcium concentrations that occur in the cytosol of stimulated cells (31, 33, 35) . These characteristics make it an attractive candidate for the activity responsible for the release of arachidonic acid from intact cells. Our previous work, and that by other investigators, suggested that PLA2 activity in endothelial cells also is regulated, in part, by protein kinase C (PKC) (36) (37) (38) .
Using the endothelial cell model, we have investigated growth-dependent alterations in arachidonic acid release and metabolism. In this work, we demonstrate that there is a dramatic decline in stimulated arachidonic acid release from phospholipids and the subsequent synthesis of PGI2 in cultured endothelial cells as they progress from an actively proliferating preconfluent state to a contact-inhibited, confluent monolayer. We find that this effect is consistent with a regulated, growth-dependent change in the activity of PLA2, a process regulated by changes in phosphorylation of the enzyme. Moreover, the low release state appears to be the usual one in vivo.
Methods
Materials. Calcium ionophore A23187, di-C17 phosphatidylcholine, arachidonic acid, docosatetraenoic acid, potato acid phosphatase (type VII), phospholipase C (Bacillus cereus), and benzoic anhydride were Cell culture. Bovine pulmonary artery endothelial cells were cultured as described (3) in medium 199 containing 25 mM Hepes with 20% fetal bovine serum, 100 U/mI penicillin, and 100 Mg/ml streptomycin. Human umbilical vein endothelial cells were cultured using a modification of the method of Jaffe et al. (4, 39) . We have described the characteristics of both of these cells in culture (3, 39) . All cells were used in primary culture except where indicated. Preconfluent cells were typically used 48 h after the initial plating when the cells diplayed an actively dividing morphology and were at a sparse density (covering < 25% of the cell area of the culture vessel). Cells progressed to confluence within 7-10 d after the initial plating and exhibited a tight, cobblestone morphology.
Measurement ofPGI2 production by cells in culture. PGI2 production by cultured cells was quantitated by RIA of 6-ketoprostaglandin Fla, the stable degradation product of PGI2, as described (40 Patton (44) . The eluents containing the individual phospholipids were collected and dried under nitrogen and used for determination of the amount of label in the subclasses of PC and PE. These fractions were derivatized to 1,2-diradyl-3-benzoylglycerols using the method of Blank et al. (45) and separated by TLC using the solvent system benzene/ hexane/diethyl ether (50:45:4). Each subclass was identified by comparison to authentic standards (diacyl, alkylacyl, and alkl-l-enyl acyl). The amount of label present in each was measured by scintillation spectroscopy. (42) . In some experiments, labeled endothelial cells were exposed to buffer (HBSS + 10 mM Hepes; pH 7.4) containing calcium ionophore (10 uM A23187) for 60 min. The organic phase of the extraction was dried under N2 and dissolved in 1.0 ml of petroleum ether. 1 ml of BF3/methanol (Supelco) was added, and the mixture was heated to 100°( for 5 min and then cooled on ice. 1 ml of water was added and the mixture was vortexed. The phases were separated by centrifugation (1,000 g; 2 min). (42) . 50 nmol of di-C17 phosphatidylcholine was added as an internal standard. The organic phase was dried under nitrogen and redissolved in 1 ml of petroleum ether and 1 ml of borontrifluoride in methanol. This mixture was heated at 1000C for 5 min and cooled on ice. Water (0.5 ml) was added and the tubes were shaken and centrifuged. The upper phase was removed and the lower phase was extracted with 1 ml of hexane. These fractions were combined and dried under nitrogen. This was resuspended in 25 jil of hexane and 1 ji was split-injected (100:1) into a gas chromatograph (model 3700; Varian Instrument Business, San Fernando, CA) fitted with a DB5 FSOT capillary column (15 m). The derivatized fatty acids were separated on a linear gradient from 140 to 2000C at 20C/min with 10 psi helium. The derivatized fatty acids were identified by comparison of retention times to those of standards. The peak areas were integrated on an integrator (3390A; Hewlett-Packard Co., Palo Alto, CA) and mass was determined by comparison with the internal standard.
Cell cycle analysis. Cells were removed from culture dishes with trypsin; the cells were centrifuged (500 g, 5 min) and resuspended in calcium-free buffer (HBSS, no calcium, 1 mM EGTA). The cells were fixed by dropwise addition of ice-cold ethanol to the cell suspension with gentle vortexing, until the suspension was 70% ethanol, and then were stored overnight at 4°C. The cells were then removed by centrifugation and the ethanol was decanted; the cells were resuspended in 0.5 ml phosphate-buffered saline. 15 1il of RNAase (ribonuclease A, type fl-A, 1 mg/ml in Tris-EDTA buffer) was added and the mixture was incubated for 30 min at 370C. Propidium iodide (0.5 ml of propidium iodide in PBS, 70 ug/ml) was added to the suspension and the mixture was incubated for 30 min on ice. The percentage of cells in each cell cycle stage was measured as described (16).
Measurement of intracellular calcium. Changes in intracellular calcium changes in response to calcium ionophore stimulation were measured using Indo-1 spectrofluorimetry as described (36) . Endothelial cells were grown on glass coverslips; sparse, preconfluent endothelial cells or confluent endothelial cells from the same isolate (that had been plated at higher density) were loaded with 1-[2-amino-5-(6-carboxyindol-2-yl)-phenoxy]-2-(2'-amino-5'-methylphenoxy)ethane-N,N,N',N'-tetraacetic acid, pentaacetoxy-methylester (Indo-l AM) (10 ILM; 1 h), washed, and placed in the perfusion chamber of a custom-built spectrofluorimeter. The excitation wavelength was 360 nm and the detection wavelengths were 410 and 500 nm. Fluorescence was recorded from single cells by the use of an iris in the emission pathway to control for any potential differences in signal that might arise as a result of differences in cell density. The cell was exposed to control buffer (HBSS + 10 mM Hepes, pH 7.4) and a baseline was recorded. The cell was then exposed to buffer containing 10 jiM bromo-A23187, a nonfluorescent analogue of A23187. The ratio 410:500, expressed in arbitrary units, is proportional to intracellular calcium concentrations (36) .
Measurement of PLA2 activity. PLA2 activity was measured in homogenates of endothelial cells using a modification of the method of Clark et al. (33) . The medium was removed from flasks of cultured endothelial cells at preconfluent and confluent points and the cells were washed with ice-cold buffer (HBSS; zero calcium; 2 mM EGTA). The cells were then scraped from the flask into the same buffer, recovered by centrifugation (500 g; 10 min) and frozen at -70°C until assayed. 500 Ml of lysis buffer (140 mM NaCl, 5 mM KC1, 2 mM EGTA, 10 mM Hepes, pH 7.4, 1 mM PMSF, 100 MM leupeptin, 1 mM DTT, and 100 jg/ml aprotinin) was added to the frozen cell pellet. The cells were disrupted by nitrogen cavitation (750 psi; 20 min) and the cell lysate was centrifuged at 100,000 g for 45 min; the supernatant (cytosolic) was removed for subsequent assay. The assay (total volume = 500 il) contained 150 mM NaCl, 2 mM CaCl2, 50 mM Hepes, pH 7.4, 2 mM DTT, 2 mg/ml fatty acid-free BSA, 2 MM 1,2-dioleoyl glycerol, and 4 jiM l-stearoyl-2-[3H]arachidonoyl phosphatidylcholine (400,000 dpm per assay). The substrate was prepared by drying the appropriate amounts of diglycerol and labeled and unlabeled l-stearoyl-2-arachidonoyl phosphatidylcholine under nitrogen. These lipids were resuspended in assay buffer and briefly sonicated in a bath sonicator. The (42) . The unreacted substrate and the product were separated using thin layer chromatography chloroform/methanol/glacial acetic acid (90:10:10). The fractions containing [3H]arachidonic acid and the substrate were scraped from the plate and the amount of radioactivity in each was measured using liquid scintillation spectroscopy. The assay was linear over time (0-30 min), the amount of cell protein (5-10 jig), and the amount of substrate hydrolyzed (< 5%). For some experiments the cell homogenate was treated with a monoclonal antibody that specifically neutralizes the cytoplasmic PLA2 activity (M12) (46) or a control antibody that binds to, but does not neutralize, the cytoplasmic PLA2 (M3-1) (46) . In those experiments, the cell lysate was incubated with the antibody (1 mg/ml) or control buffer for 60 min on ice. This mixture was then assayed for PLA2 activity as above. For Measurement of PI-specific phospholipase C (PI-PLC) activity. PI-PLC activity was measured using the method of Hoffman et al. (47) . Reaction mixtures contained 250 jAM PI, 60,000-100,000 dpm L-a-[myo-inositol-2-3H(N)]PI (220 dpm/pmol), 1 mg/ml of sodium deoxylcholate, 1 mM CaC12, 0.5 mg/ml of bovine serum albumin, 100 mM NaCl, 50 mM Hepes, pH 7.0, and 5-25 jig of cell protein in a total volume of 200 ,ul. The reaction was begun by the addition of the endothelial cell homogenate (20 /il) and was allowed to proceed at 37°C for 10 min. The reaction was terminated by the addition of 1 ml of CHC13/ methanol/concentrated HCl (100:100:6) followed by 0.3 ml of 1 N HCl containing 5 mM EGTA. The mixture was vortexed and centrifuged (500 g, 5 min). A portion of the aqueous phase (400 jd) was removed for scintillation counting. The assay was linear with respect to time and the amount of cell homogenate added with < 5% hydrolysis of the substrate. Purified PI-PLC from ram seminal vesicles (47) (48) and were electrophoretically transferred to a polyvinyldifluoride membrane (Immobilon; Millipore Corp., Bedford, MA). Immunoblotting was performed as described (48) using, in turn, monoclonal antibodies that specifically recognize prostaglandin H2 synthetase type I, prostaglandin H2 synthetase type II, and the cytoplasmic PLA2.
The immunoblots were developed using an enhanced chemiluminescent assay (Amersham Corp., Arlington Heights, IL). For estimation of the relative amounts of mRNA coding for the prostaglandin H2 synthetases I and H and the cytoplasmic PLA2, mRNA was extracted from preconfluent and confluent cells from the same isolate using guanidinium thiocyanate (49) and cDNA was prepared as described using murine leukemia virus reverse transcriptase (49) . Polymerase chain reaction amplification of cDNA was performed with primers recognizing unique sequences of prostaglandin H2 synthetase I (50-52), prostaglandin H2 synthetase II (13) , or the cytoplasmic PLA2 (34) . Primers specific for glyceraldehyde-3-phosphate dehydrogenase (53) were used as a control.
The amplified cDNAs were separated on a 1.2% agarose gel and stained with ethidium bromide. Estimates of the relative amounts of message were made by comparing the intensity of the bands specific for each product, using glyceraldehyde-3-phosphate dehydrogenase as a denominator.
Results
Stimulated production ofprostacyclin decreases as endothelial cells progress to confluence in culture. Some investigators have reported that stimulated production of prostacyclin by endothelial cells changes with increasing time in culture or with repeated passage of the cells although the pattern of change is variable from study to study (1, (14) (15) (16) . To clarify this, we first examined the stimulated production of prostacyclin (PGI2), the major arachidonic acid metabolite, by endothelial cells as they progressed from an actively dividing, preconfluent state to a contact-inhibited monolayer. We stimulated bovine endothelial cells with calcium ionophore and measured the amount of 6-keto PGF1,<, the stable hydrolysis product of PGI2. Actively dividing, sparse cells produced 13 .2±1.7 ng of PGI2/nmol of cellular phospholipid (mean+SD; n = 6). In contrast, monolayers that were confluent produced only 6.1±0.7 ng PGI2/nmol of cellular phospholipid (n = 6; P > 0.001). We asked whether this change was limited to bovine cells from pulmonary artery or was a more general one. To assess this, we examined human endothelial cells derived from umbilical vein under the same conditions and found that they demonstrated the same phenomenon: PGI2 formation per cell was twice as high in preconfluent cells as in confluent cells. To exclude different kinetics of release under the two growth conditions as an explanation for this effect, we performed a time course and found that release was > 95% complete within 1 h for cells at either growth state (not shown). The diminished release at confluence was apparent regardless of what measure of cell mass was used (cellular protein or phospholipid, or cell number). These experiments were performed with calcium ionophore A23187 to avoid any possible differences due to quantitative or qualitative differences in receptors for other agonists that mediate arachidonic acid release.
The observed differences in prostacyclin formation could have arisen from differences in the initial release of arachidonic acid from its phospholipid storage site or from differences in the subsequent metabolism of the arachidonic acid (e.g., differences in the activity of prostaglandin H2 synthetase or prostacyclin synthetase). To test the latter hypothesis, we measured the amount of prostacyclin produced by preconfluent and confluent cells when they were supplied with exogenous arachidonic acid. Prostacyclin formation (normalized to the amount of cell protein) was no different in the preconfluent cells compared with the confluent cells when exogenous arachidonic acid was provided (Fig. 1) . As before, controls exposed to a calcium ionophore showed a marked decrease in the amount of prostacyclin formed in confluent compared with preconfluent cells. In addition, we quantitated the amounts of prostaglandin H2 synthetase (both prostaglandin H2 synthetase and the inducible prostaglandin H2 synthetase [13] ) by Western blotting and found that the amounts in preconfluent cells were no greater than those in confluent cells (not shown). Similarly, PCR amplification of mRNA for prostaglandin H2 synthetase and the inducible prostaglandin H2 synthetase (13) (Fig. 2) (Fig. 3, a-d) . In both cases, there was a net redistribution of [3H]arachidonic acid from PC (and, to a lesser extent, PI) to PE (Fig. 3, a and b) . Similarly, there was a net loss of [3H]arachidonic acid from triglyceride over the same period (Fig. 3, c and d to [3H]docosatetraenoate and found it to be the same in preconfluent and confluent cells (not shown).
We also considered the possibility that confluent cells are relatively depleted of arachidonic acid. To assess this, and to evaluate the correlation of radiolabeled arachidonic acid with endogenous, we measured the fatty acid composition of the cells at different growth states with GLC. We found that their arachidonic acid content increased from 11.3 to 17.1 mole percent during the progression from a preconfluent to a confluent state. This probably was due to incorporation of arachidonic acid from the serum in the medium. We also used this method to examine arachidonic acid release. Preconfluent or confluent cultures were stimulated with the calcium ionophore, and then their content of arachidonic acid was measured after release. The mole percent of arachidonic acid fell from 11 (Table IV) . In contrast, cells passed to high density released only 12.1% of label (Table IV) and the decreased release at higher cell density was seen in each phospholipid (Table IV) , similar to results in cells progressing to confluence in primary culture. From these results we can reject the hypothesis that the decreasing release was simply a consequence of increasing time in culture, as the time in culture was identical.
In subsequent studies we asked whether this change (i.e., decreased release) was reversible. To do so, we measured the stimulated production of PGI2 by endothelial cells that were converted from the quiescent, confluent monolayer to an actively proliferating state. Confluent monolayers were wounded in a cross-hatch pattern with a Teflon rake; the cells proliferated to cover the denuded areas. During this period, stimulated production of PGI2 was measured and compared with unwounded controls. The stimulated production of PGI2 (per cell mass) Growth Endothelial cells in vivo form a tightly confluent layer, which is important for its role as a barrier between blood and the tissues and would be analogous to the confluent phenotype in cultured cells. We asked whether the cells in the in vivo state displayed high or low release of arachidonic acid when stimulated. We placed a bovine pulmonary artery in a customdesigned template that we have described previously (3) . In this circumstance the endothelium forms the floor of a plastic well the size of a cell culture dish but remains in situ on the blood vessel. Endothelial cells examined under these experimental conditions produced 151.5±8.3 ng 6-keto PGF1J106 cells in response to calcium ionophore (10 ,tM A23187; 60 min) (n = 6) which was nearly identical to that seen in confluent cultured cells (145.4+9.4 ng 6-keto PGFIe/106 cells; n = 6). Thus, we conclude that the arachidonic acid release phenotype is a function of the proliferative state of the cell and is reversed by changes in the growth state, such as the proliferative state that occurs in a quiescent monolayer after mechanical injury.
Characterization We next tested the possibility that the growth-dependent changes were a consequence of an autocrine process such as an arachidonic acid metabolite causing feedback inhibition of arachidonic acid release. Exposure of endothelial cells to PGI2, PGE2, or PGF2<. (100 ng/ml), the major cyclooxygenase products in endothelial cells, or the stable PGI2 analogue, carbacyclin (100 ng/ml), did not inhibit the subsequent formation of prostacyclin in response to stimulation with calcium ionophore (not shown).
Given the striking growth-dependent alterations in arachi- M3-4 binds to the PLA2 but does not inhibit its activity [46] . The small increase in activity seen with binding of M3-4 is similar to other reports [46] .) After incubation with the antibodies or control, the amount of The decrease in the amount of PLA2 activity with the progression to confluence could have resulted from a decreased amount of enzyme or from a regulated change in the activity. Measurements of the amounts of the cytosolic PLA2 in preconfluent and confluent cells by Western blotting showed no difference (not shown); in addition, the amounts of mRNA for this enzyme were no different at the different growth states when measured by PCR amplification (not shown). These data suggest that the differences in activity arise from a regulated change in the PLA2 rather than differences in the amount of turnover of the enzyme. Recently several groups have shown that the PLA2 is regulated by phosphorylation (46, 59, 60) . To test whether differences in phosphorylation of the PLA2 were responsible for the changes that we observed, we treated endothelial cell homogenates with phosphatase and measured the residual PLA2 activity. Phosphatase treatment dramatically decreased the PLA2 activity in homogenates from preconfluent cells (Fig. 7) . Importantly, the activity in homogenates from preconfluent endothelial cells that remained after phosphatase treatment was approximately that found in homogenates of confluent cells (Fig. 7) . To further confirm the differences in the regulation of PLA2 by phosphorylation, we exploited the observation by other 97 kD Figure 8 . The phosphorylated form of PLA2 is in greater abundance in preconfluent endothelial cells than confluent cells. Preconfluent human umbilical vein endothelial cells (2 d after plating) were harvested, placed in SDS sample buffer, and frozen. Confluent endothelial cells (8 d after plating) from the same isolate were later harvested in identical fashion. Proteins were separated by SDS-PAGE (10% gel) with prolonged electrophoresis to separate the phosphorylated (higher apparent molecular mass, asterisk) from the nonphosphorylated form (46, 59) . The proteins were then electrophoretically transferred to a polyvinyldifluoride membrane and subjected to immunoblotting using the monoclonal antibody M3-1. Although the relative amounts of the two forms of the PLA2 differed from isolate to isolate, the relative amount of the phosphorylated form was consistently greater in preconfluent cells compared with the confluent cells in five isolates examined.
workers that the phosphorylated form of the PLA2 migrates less rapidly on SDS gel than the nonphosphorylated protein (46, 59) . SDS-PAGE of preconfluent and confluent endothelial cell proteins, followed by Western blotting for the PLA2, demonstrated that the upper band (the phosphorylated form) was present in greater amounts in the preconfluent cells compared with the confluent cells (Fig. 8) . These data indicate that the growthdependent differences in arachidonic acid release arise from a regulated alteration in the activity of the arachidonate-specific PLA2 and that this regulation is a consequence of differences in phosphorylation, presumably a consequence of protein kinase(s) activity. This is consistent with other studies where we have found that the growth-dependent change in activity is consistent with a process regulated by PKC (61).
Discussion
We found that stimulated release of arachidonic acid and the consequent production of PGI2 decrease as cells progress to confluence in culture. This was demonstrated using both metabolic labeling with [3H]arachidonic acid and mass measurements including gas chromatography of arachidonic acid content and radioimmunoassay of the major arachidonic acid metabolite. The decrease in release occurred as cells progressed from a sparse, actively dividing culture to a quiescent, contactinhibited monolayer and related to the growth state of the cell as measured by cell cycle analysis. Control experiments demonstrated that the alteration in release of [3H]arachidonic acid was not a result of a difference in distribution of label at the different growth states and confirmed that arachidonic acid was not sequestered into a poorly mobilized pool. In fact, these studies demonstrate that arachidonic acid release from preconfluent cells was greater in each phospholipid and phospholipid subclass (compared with confluent cells). These data do not exclude the possibility that the arachidonic acid might be sequestered into a geographically defined pool within the cell. Currently, there is no way to directly test this possibility. However, the [3H]arachidonic acid-labeling studies demonstrate that uptake, distribution, and redistribution of label is identical in both preconfluent and confluent cells. If there were differences in the topographic distribution of arachidonic acid at the two growth 1898 Whatley, Satoh, Zimmerman, McIntyre, and Prescott Confluent states, one would predict that these distributions would also be different.
In other control experiments, we found, as others have (56) , that a small percentage of the [3H]arachidonic acid is rapidly metabolized to [3H] docosatetraenoate. This conversion of arachidonic acid occurred to the same degree in both preconfluent and confluent cells; in addition, the docosatetraenoate was released in a fashion identical to arachidonic acid at both growth states. These data indicate that differences in conversion of label are not responsible for the differences in the stimulated release of [3H]arachidonic acid at the different growth states. Moreover, the growth-dependent differences in arachidonic acid release were seen when arachidonic acid content was measured by gas chromatography, a measurement that is not affected by metabolism of label.
All of these studies indicate that the changes in the stimulated release of arachidonic acid arise from a regulated change within the cell, occurring at the initial release of arachidonic acid from its phospholipid storage site. As arachidonic acid is selectively esterified at the sn-2 position of phospholipids, the most direct mechanism for release would be a PLA2. Alternatively, sequential action of a PLC and diglyceride lipase (7, 25) or PLD, phosphatidic acid phosphatase and a diglyceride lipase (7, 29) would also result in arachidonic acid release. PLC activity did not change significantly at the different growth states; conversely, we found that in vitro PLA2 activity did decrease in concert with the decreased release measured in metabolic labeling studies. Although phospholipase activity measured by an optimized in vitro assay may not reflect the activity in the whole cell where a variety of factors (e.g., substrate concentration, cofactors) are likely be different than in an in vitro assay, our results are consistent with the possibility that the differences in arachidonic acid release and PGI2 formation at the different growth states arise from a regulated change in PLA2. Recently, several groups have purified and cloned a calcium-dependent cytoplasmic PLA2 that is an attractive candidate for the enzyme responsible for arachidonic acid release in several cell types (30, 33, 34) . Currently, the mechanisms that regulate the activity of this enzyme are incompletely understood, although there is increasing evidence that this step is regulated by phosphorylation, a step involving PKC, probably in concert with other protein kinases (59, 60) , particularly mitogen-activated protein kinase (62, 63) . Our data presented here and previous data that are consistent with a regulatory role for PKC in this process (61) (10) and perhaps colon cancers (11) , depend on prostaglandins as a growth signal. Our data exclude such an autocrine role for PGI2, PGE2, or PGF2, as feedback inhibitors of arachidonic acid release; conversely, inhibition of the cyclooxygenase pathway in these cells (and the consequent inhibition of a basal formation of cyclooxygenase products) did not affect cell proliferation. However, these data do not exclude an autocrine role for arachidonic acid metabolites produced by pathways other than cyclooxygenase (e.g., hydroxyeicosatetraeonic acid, hydroperoxyeicosatetraenoic acids). In addition to cyclooxygenase, other pathways for arachidonic acid (and other long chain unsaturated fatty acids) metabolism are present in endothelial cells and regulatory roles for several of these products have been proposed (7, 66, 67) .
